That program has been back-burnered or “deprioritized” following a strategic review of the combined companies’ pipelines, with study status to be updated on the ClinicalTrials.gov page of a Phase II ...

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...

The Council for the Indian School Certificate Examinations (CISCE) has released the ISC Computer Science (Subject Code - 868) for the Year 2027 evaluation cycle. It is designed specifically to make ...

Model collapse AI training data risk grows as Meta’s Brand Memory ad tools flood the open web with synthetic content, ...

As AI transforms education, we must redefine intelligence beyond biological limits and embrace cognitive functions across ...

The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most ...

In Barrie's Peter Pan, Wendy sewed Peter's mischievous shadow back on his feet. Wendy saw what was incomplete and chose to ...

Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a ...

"Our mission at Longevity Investors is to connect the people shaping the future of human health and longevity — investors, entrepreneurs, scientists, family offices, and industry leaders." ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

In the AI value chain, application-layer leaders like Palantir and ServiceNow may win long term as chip/cloud margins ...

New VentureBeat survey data: 85% of enterprises run contested AI platforms with no single owner, and only 10% can ...